Biotech & Pharma · Week of Nov 2, 2026
Q3 results put cash runways and 2027 FDA timelines in focus
Third-quarter earnings dominated, with companies reporting cash runways and FDA filing timelines, alongside late-stage data from J&J and AbbVie.
Most of this week's releases were third-quarter 2026 results, and the main points in them were cash and regulatory timing. Seres Therapeutics says its cash funds operations through the first quarter of 2027. Intensity Therapeutics reported $8.5 million in cash. Aprea Therapeutics says its runway extends into the first quarter of 2028. IDEAYA Biosciences and Viridian Therapeutics reported balances of about $1.15 billion and $955.2 million respectively. Several companies pointed to FDA milestones expected in early 2027: GRAIL anticipates a decision on its Galleri test, Viridian plans a BLA for elegrobart, and Seres plans to submit a SER-155 study design.
Outside earnings, Johnson & Johnson reported Phase 3 psoriatic arthritis data for its oral peptide ICOTYDE at ACR Convergence 2026. AbbVie's Allergan Aesthetics presented Phase 4 results in patients on GLP-1 medications at ASDS 2026. Trial restructuring was another thread. IDEAYA is closing its Phase 3 OptimUM-010 trial, and Intensity resumed enrollment in two studies after a funding-related pause.
AbbVie
Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
Allergan Aesthetics, an AbbVie company, reported results from two Phase 4 studies, HARMONY IN DIVERSITY and HALO, presented at ASDS 2026. In the studies, adults on GLP-1 medications showed FACE-Q satisfaction improvements of 42.4 and 39.6 points after aesthetic treatment. The company says most treatment-related adverse events were mild and nonserious.
Johnson & Johnson
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Johnson & Johnson says once-daily oral ICOTYDE (icotrokinra) met the primary endpoint in the Phase 3 ICONIC-PsA 1 study in biologic-naive adults with active psoriatic arthritis. At Week 16, 58% of patients on ICOTYDE achieved ACR20 versus 41% on placebo. The drug is approved in the U.S. for plaque psoriasis but not for psoriatic arthritis.
Seres Therapeutics, Inc.
SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC)
Seres Therapeutics reported a third-quarter net loss of $16.3 million and $17.5 million in cash as of September 30, 2026, plus a $12.5 million payment from Nestlé in October. The company says this funds operations through the first quarter of 2027. It plans a funding-dependent study of SER-155 to prevent irEC and expects to submit the design to the FDA in that quarter.
Intensity Therapeutics Inc.
Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Intensity Therapeutics reported a third-quarter net loss of $3.5 million and cash of $8.5 million. The company says enrollment resumed in its Phase 3 INVINCIBLE-3 and Phase 2 INVINCIBLE-4 studies of INT230-6 after a pause that began in March 2025 due to funding constraints.
IDEAYA Biosciences, Inc.
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
IDEAYA Biosciences reported a third-quarter net loss of $125.7 million and says it submitted an NDA for darovasertib plus crizotinib in metastatic uveal melanoma. It is closing the Phase 3 OptimUM-010 trial, with estimated savings of $100-125 million. It plans two Phase 3 trials of IDE849 by year end, with cash runway guidance into 2030 unchanged.
GRAIL, Inc.
GRAIL Reports Third Quarter 2026 Financial Results
GRAIL reported third-quarter revenue of $37.5 million and a net loss of $103.6 million. Galleri test volume grew about 24% year-over-year to more than 56,000 tests. An FDA advisory panel voted in favor of approving Galleri in September, and the company anticipates an FDA decision by early Q1 2027.
Aprea Therapeutics, Inc.
Aprea Therapeutics Announces Third Quarter 2026 Financial Results
Aprea Therapeutics reported a third-quarter net loss of $4.8 million and cash of $37.8 million, with runway expected into the first quarter of 2028. It expanded its Phase 1 ACESOT-1051 trial of the WEE1 inhibitor APR-1051 from three to nine sites. Updated interim results are scheduled for ENA 2026 on November 20, 2026.
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
Viridian Therapeutics reported $24.7 million in Lumvoa net product revenue in its first quarter of launch in thyroid eye disease, and a net loss of $101.2 million. The company expects to submit a BLA for elegrobart in TED in Q1 2027. It held $955.2 million in cash, cash equivalents and marketable securities.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Insights Emerge reporting.